BillionToOne

BillionToOne is a company that specializes in developing a molecular counter platform for upgrading the resolution of cell-free DNA testing. Their prenatal testing procedure focuses on quantitative biology and statistical learning methods to optimize the signal-to-noise ratio and detect single-gene disorders. The company's innovative technology enables expecting mothers to detect disorders like sickle-cell disease, beta-thalassemia, spinal muscular atrophy and cystic fibrosis through a simple blood test. This empowers expecting mothers with vital information about their baby's health and helps doctors make informed decisions for better outcomes. BillionToOne's cutting-edge molecular counter technology is poised to revolutionize prenatal testing and improve the lives of countless families around the world.